Abstract
The HIV-1 Tat protein hijacks the Super Elongation Complex (SEC) to stimulate viral transcription and replication. However, the mechanisms underlying Tat activation and inactivation, which mediate HIV-1 productive and latent infection, respectively, remain incompletely understood. Here, through a targeted complementary DNA (cDNA) expression screening, we identify PRMT2 as a key suppressor of Tat activation, thus contributing to proviral latency in multiple cell line latency models and in HIV-1-infected patient CD4<sup>+</sup> T cells. Our data reveal that the transcriptional activity of Tat is oppositely regulated by NPM1-mediated nucleolar retention and AFF4-induced phase separation in the nucleoplasm. PRMT2 preferentially methylates Tat arginine 52 (R52) to reinforce its nucleolar sequestration while simultaneously counteracting its incorporation into the SEC droplets, thereby leading to its functional inactivation to promote proviral latency. Thus, our studies unveil a central and unappreciated role for Tat methylation by PRMT2 in connecting its subnuclear distribution, liquid droplet formation, and transactivating function, which could be therapeutically targeted to eradicate latent viral reservoirs.
Introduction
Antiretroviral therapy (ART) effectively suppresses HIV-1 replication but fails to eradicate the virus due to the persistence of latent reservoirs in resting memory CD4+ T cells. The viral transactivator protein, Tat, is essential for efficient viral transcription by recruiting the Super Elongation Complex (SEC) to the viral promoter. During latency, Tat activity is suppressed, maintaining the virus in a dormant state. Understanding the molecular mechanisms that govern Tat inactivation is crucial for developing "shock and kill" strategies to eliminate these reservoirs.
Methods
To identify host factors regulating Tat, a targeted cDNA expression library of human enzymes was screened for their ability to suppress Tat-mediated activation of the HIV-1 long terminal repeat (LTR) promoter. Validation was performed using CRISPR/Cas9-mediated knockout and shRNA-mediated knockdown in Jurkat-derived latency models (E4, 2D10) and primary CD4+ T cells from HIV-infected patients on suppressive ART. The impact of PRMT2 on Tat subnuclear localization and phase separation was assessed using in vitro droplet assays and immunofluorescence. Mass spectrometry identified specific methylation sites on Tat.
Results
Identification of PRMT2 as a Suppressor of Tat Activity
The cDNA screen identified Protein Arginine Methyltransferase 2 (PRMT2) as a potent inhibitor of Tat-dependent transcription. As shown in Figure 2, among the PRMT family members, PRMT2 exhibited the most significant and specific suppression of Tat-induced luciferase activity. This suppression was dose-dependent and required the catalytic activity of the enzyme, as active-site mutants failed to inhibit Tat.
PRMT2 Depletion Reverses HIV-1 Latency
To determine if PRMT2 maintains latency, the researchers depleted PRMT2 using shRNAs. Knockdown of PRMT2 significantly increased spontaneous HIV-1 reactivation in latency models (up to ~20% in some models) and sensitized cells to other latency-reversing agents (LRAs). This effect was accompanied by a significant increase in Tat-mediated transcriptional activity (Figure 5).
Mechanism: Nucleolar Sequestration and Phase Separation
The study revealed that PRMT2 methylates Tat at Arginine 52 (R52). This modification increases Tat's interaction with the nucleolar protein NPM1, trapping Tat within the nucleolus. Consequently, Tat is prevented from exiting into the nucleoplasm, where it normally undergoes phase separation to join the SEC. By reinforcing nucleolar sequestration and counteracting SEC droplet formation, PRMT2 effectively silences viral transcription.
Discussion
This work identifies PRMT2 as a critical "gatekeeper" of HIV-1 latency. By chemically modifying Tat, PRMT2 regulates its subnuclear distribution and ability to form functional transcriptional condensates. The high levels of PRMT2 in resting T cells contribute to the maintenance of the latent reservoir. Although selective PRMT2 inhibitors are currently lacking, the development of such compounds could provide a novel therapeutic avenue for reactivating latent HIV-1 as part of a curative strategy.
Summary updated